US Military HIV Research Program (MHRP), Department of Retrovirology, Armed Forces Research Institute of Medical Sciences, 315/6 Rajvithi Road, Bangkok, 10400, Thailand.
Expert Rev Vaccines. 2010 Sep;9(9):1055-69. doi: 10.1586/erv.10.106.
Challenges in the development of an effective HIV-1 vaccine are myriad with significant hurdles posed by viral diversity, the lack of a human correlate of protection and difficulty in creating immunogens capable of eliciting broadly neutralizing antibodies. The implicit requirement for novel approaches to these problems has resulted in vaccine candidates designed to elicit cellular and/or humoral immune responses, to include recombinant DNA, viral and bacterial vectors, and subunit proteins. Here, we review data from clinical studies primarily of poxvirus and adenovirus vector vaccines, used in a heterologous prime-boost combination strategy. Currently, this strategy appears to hold the most promise for an effective vaccine based on results from immunogenicity testing and nonhuman primate challenge models, as well as the modest efficacy recently observed in the Thai prime-boost trial.
开发有效的 HIV-1 疫苗面临着诸多挑战，包括病毒多样性、缺乏人类保护相关物和难以制造能够引发广泛中和抗体的免疫原等。这些问题需要新的方法来解决，因此设计了候选疫苗来引发细胞和/或体液免疫反应，包括重组 DNA、病毒和细菌载体以及亚单位蛋白。在这里，我们主要回顾了痘病毒和腺病毒载体疫苗的临床研究数据，这些疫苗采用了异源初免-加强的组合策略。目前，根据免疫原性测试和非人类灵长类动物挑战模型的结果，以及最近在泰国初免-加强试验中观察到的适度疗效，这种策略似乎最有希望开发出有效的疫苗。
